A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

Marsden Eye Specialists, Parramatta, New South Wales

Royal Adelaide Hospital, Adelaide, South Australia